4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...

4D-150 Phase 3 program is on track: 4FRONT‑1 is fully enrolled with a readout expected in H1 2027, 4FRONT‑2 enrollment should complete in H2 2026 with a readout in H2 2027, and the program was upsized ...